Literature DB >> 24176298

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

Dietmar Pils1, Anna Bachmayr-Heyda2, Katharina Auer2, Martin Svoboda3, Veronika Auner2, Gudrun Hager2, Eva Obermayr4, Angelika Reiner5, Alexander Reinthaller2, Paul Speiser2, Ioana Braicu6, Jalid Sehouli6, Sandrina Lambrechts7, Ignace Vergote7, Sven Mahner8, Astrid Berger9, Dan Cacsire Castillo-Tong2, Robert Zeillinger4.   

Abstract

Cyclin E, coded by the genes CCNE1 and CCNE2, is the main regulator for transition from G1 to S phase determining cell division. CCNE1 and CCNE2 are known oncogenes in many cancer entities. Especially CCNE1 has frequently been associated with gene amplifications in various malignancies, emphasising its role as a putative oncogene. We determined gene expression and copy number of CCNE1 and CCNE2 by quantitative polymerase chain reaction (PCR) from 172 International Federation of Obstetrics and Gynecology (FIGO) II/III/IV stage serous epithelial ovarian cancer (EOC) tissues and analysed its impact on outcome. Furthermore, whole transcriptome gene expression changes correlating with CCNE1 expression were determined by microarray technology, interpreted by Signalling Pathway Impact Analysis (SPIA), Tool for Inferring Network of Genes (TINGe), and illustrated by hive plots. Protein-protein interaction (PPI) networks were also used for the interpretation. Interestingly, and contradictory to most reports and intuitive expectations, high CCNE1 expression correlated with better overall survival (p=0.005) if corrected for usual clinicopathologic parameters and a molecular subclassification. Using different grading systems or only high graded tumours had no impact on this correlation. Copy number of CCNE1 was increased in 25% of cases which correlated highly significantly with expression but showed no impact on outcome. CCNE2 had no impact on outcomes at all. Whole genome transcriptome analysis revealed 1872 differentially expressed genes correlated to CCNE1 expression, which were significantly enriched with genes from five pathways (e.g. cell cycle and viral carcinogenesis pathway were up-regulated and the Fanconi anaemia pathway was down-regulated). High CCNE1 gene expression is a significant and independent predictor for prolonged overall survival in FIGO III/IV EOC patients. This upside down impact of CCNE1 on survival probably reflects the special characteristic of EOC with tumour dissemination in the near anaerobic peritoneal cavity as the predominant cause of death, compared to other cancer entities where distant metastasis are predominantly lethal.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCNE1; Molecular subclass; Ovarian cancer; Prognosis; Proliferation

Mesh:

Substances:

Year:  2013        PMID: 24176298     DOI: 10.1016/j.ejca.2013.09.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  24 in total

Review 1.  Epithelial ovarian cancer - more data, more questions?

Authors:  Stefanie Aust; Dietmar Pils
Journal:  Wien Med Wochenschr       Date:  2014-11-13

2.  Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA.

Authors:  Gábor Boros; Edit Miko; Hiromi Muramatsu; Drew Weissman; Eszter Emri; Gijsbertus T J van der Horst; Andrea Szegedi; Irén Horkay; Gabriella Emri; Katalin Karikó; Éva Remenyik
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

3.  Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.

Authors:  Stefanie Aust; Katharina Auer; Anna Bachmayr-Heyda; Carsten Denkert; Jalid Sehouli; Ioana Braicu; Sven Mahner; Sandrina Lambrechts; Ignace Vergote; Christoph Grimm; Reinhard Horvat; Dan Cacsire Castillo-Tong; Robert Zeillinger; Dietmar Pils
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

4.  Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.

Authors:  Liu Yang; Dongdong Fang; Huijun Chen; Yiyu Lu; Zheng Dong; Han-Fei Ding; Qing Jing; Shi-Bing Su; Shuang Huang
Journal:  Oncotarget       Date:  2015-08-28

5.  Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread.

Authors:  Anna Bachmayr-Heyda; Katharina Auer; Nyamdelger Sukhbaatar; Stefanie Aust; Simon Deycmar; Agnes T Reiner; Stephan Polterauer; Sabine Dekan; Dietmar Pils
Journal:  Oncotarget       Date:  2016-06-28

6.  A multidimensional integration analysis reveals potential bridging targets in the process of colorectal cancer liver metastasis.

Authors:  Bo Gao; Tian Yu; Dongbo Xue; Boshi Sun; Qin Shao; Hani Choudhry; Victoria Marcus; Jiannis Ragoussis; Yuguo Zhang; Weihui Zhang; Zu-Hua Gao
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

Review 7.  The diverse roles of SPOP in prostate cancer and kidney cancer.

Authors:  Zhiwei Wang; Yizuo Song; Miaomiao Ye; Xiaoming Dai; Xueqiong Zhu; Wenyi Wei
Journal:  Nat Rev Urol       Date:  2020-04-30       Impact factor: 14.432

8.  Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.

Authors:  Jun Lu; Yongfeng Ding; Yanyan Chen; Junjie Jiang; Yiran Chen; Yingying Huang; Mengjie Wu; Chengzhi Li; Mei Kong; Wenyi Zhao; Haohao Wang; Jing Zhang; Zhongqi Li; Yimin Lu; Xiongfei Yu; Ketao Jin; Donghui Zhou; Tianhua Zhou; Fei Teng; Haibin Zhang; Zhan Zhou; Haiyong Wang; Lisong Teng
Journal:  Nat Commun       Date:  2021-06-24       Impact factor: 14.919

9.  Failure of Elevating Calcium Induces Oxidative Stress Tolerance and Imparts Cisplatin Resistance in Ovarian Cancer Cells.

Authors:  Liwei Ma; Hongjun Wang; Chunyan Wang; Jing Su; Qi Xie; Lu Xu; Yang Yu; Shibing Liu; Songyan Li; Ye Xu; Zhixin Li
Journal:  Aging Dis       Date:  2016-05-27       Impact factor: 6.745

10.  AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.

Authors:  Martin Svoboda; Anastasia Meshcheryakova; Georg Heinze; Markus Jaritz; Dietmar Pils; Dan Cacsire Castillo-Tong; Gudrun Hager; Theresia Thalhammer; Erika Jensen-Jarolim; Peter Birner; Ioana Braicu; Jalid Sehouli; Sandrina Lambrechts; Ignace Vergote; Sven Mahner; Philip Zimmermann; Robert Zeillinger; Diana Mechtcheriakova
Journal:  BMC Genomics       Date:  2016-08-16       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.